Quality of life after treatment
Quality of life after a lymphoma treatment depends on several factors: the patient’s age, the presence of other medical conditions, the type of response to therapy (partial or complete) and its duration, social circumstances, the “intensity” of the treatment pathway, and any post-therapy complications.
To monitor quality of life, the hematologist-oncologist will continue to follow the patient through what is known as follow-up (periodic post-treatment evaluation), during which regular check-ups will be performed and any necessary therapies prescribed. During this phase, it is not uncommon for patients to feel anxious (due to fear of disease recurrence) and at the same time “neglected” because of the reduced frequency of check-ups in cases of a good response.
Communication with one’s physician is always essential, both for reassurance regarding the timing and methods of follow-up visits and for monitoring any long-term side effects of treatment.
Long-term side effects
The term “Long Term Effects” refers to all conditions resulting from chemo-radiotherapy that arise after treatment and persist over time.
The main possible late side effects can be divided into four categories:
Second Malignancies:these are typically late events, appearing 10 or more years after treatment, with an increased risk compared to the general population that may persist for up to 30 years after the end of therapy. The most common include breast cancer, lung cancer, and gastrointestinal cancers. Radiotherapy and alkylating agents are the treatments most frequently implicated. Lifestyle habits such as smoking and alcohol consumption further increase the risk, particularly for lung and gastrointestinal cancers.
Endocrine Disorders: some therapies may promote the development of dysfunctions in endocrine glands responsible for hormone production.
Skin Conditions: certain chemotherapeutic agents may affect the skin, leading to changes in pigmentation, a tendency toward dryness, and increased sensitivity to sunlight exposure.
Cardiac and Pulmonary Diseases: some anticancer drugs may induce cardiotoxicity. This may occur with both older-generation drugs, such as anthracyclines, and newer-generation agents, which are generally considered more selective.
To prevent or manage these effects, monitoring is planned both during treatment and throughout the post-treatment follow-up phase. A healthy lifestyle (balanced diet, regular physical activity, reduced alcohol intake, and smoking cessation) supports both prevention and management of these conditions.
After therapy, during follow-up, certain monitoring tests are routinely scheduled. Their type and frequency depend on the chemotherapy received. These typically include:
- Cardiology evaluation and echocardiogram
- Thyroid function tests (FT3, FT4, TSH) and, if needed, thyroid ultrasound
- Pulmonary evaluation (spirometry with assessment of lung volumes)
Attention: even if the information provided has been verified by the Foundation’s doctors, every decision and therapy must be individualized and monitored for each patient by the attending physician. We ask you to always refer to your doctor because the information offered cannot be replaced, in any way, by doctor / patient relationship.